ALF in Children: Etiology and Management

Dr Naresh Shanmugam

DCH, DNB(Paed), FRCPCH, Dip.Nut.Medicine(UK), CCT(UK), CSST(UK)., Director : Women and Children Division Paediatric Hepatologist and Gastroenterologist, Dr Rela Institute and Medical Centre, Chennai





ALF in children

Definitions

• Etiology of ALF

• Management



Acute Liver Failure

Massive liver necrosis with encephalopathy developing within 8 weeks from the first signs of illness in a patient without underlying chronic liver disease



Acute Liver Failure in Children

Multisystem disorder in which severe acute impairment of liver function with or without encephalopathy occurs in association with hepatocellular necrosis in a patient with no recognised underlying chronic liver disease



Practical problem

- Patient Hepatitis A
- Jaundice 350 micromol
- AST >1000

Should be we call it Acute hepatitis or ALF



Hepatitis



The Paediatric Acute Liver Failure (PALF) study group

 (i) Hepatic-based coagulopathy defined as a prothrombin time (PT) ≥ 15 seconds or international normalized ratio (INR) ≥ 1.5 not corrected by Vitamin K in the presence of clinical HE or a PT ≥20 seconds or INR ≥2.0 regardless of the presence or absence of clinical HE,

(ii) Biochemical evidence of acute liver injury,

(iii) No known evidence of chronic liver disease



















1. Initial Event

Infection (bact./viral)
Bleeding
Intoxication
Ischemia
other

3. Secondary Organdysfunctions

Brain (HE, Edema)
Kidneys (HRS)
Cardiovascular system (SVRI↓, MAP↓, CI↑)
Bone marrow (Depression)
Immune system (Activation/Paralysis)
Liver (Inflammation, Necrosis, Apoptosis) 2. Toxin-concentration 1

Hydrophobic substances •Hydrophobic bile acids •Bilirubin **Mathematical States of States and States Mathematical States** plasmatic NO •Prostacycline **ficious cycle of autointoxication** •Indol/Phenol-**Metabolits** •Toxic fatty acids •Thiols Digoxin/Diazepamlike subst. Hydrophilic substances

•Ammonia •Lactate •AAA



Aetiology

Aetiology	Age category				
	Neonate (≤28 days)	Infant (29 days to 1 year)	Child (1.1-12 years)	Adolescent (12.1-18 years)	
Autoimmune	0	0	9	4	13
Indeterminate	2	8	41	17	68
Wilson's	0	0	6	4	10
Drug	1	6	19	25	51
NH	17	0	0	0	17
Metabolic	5	3	6	1	15
Viral	10	4	8	1	23
Haem Malig	6	1	1	0	8
Misc	1	1	5	3	10
Total	42	23	95	55	215

Aetiology and outcome of NLF at King's College Hospital (1990-2007)





Metabolic

GAL-1-PUT deficiency

Tyrosinemia type 1

Defect in fumaryl acetoacetate hydrolase urine Succinyl acetone diagnostic High AFP NTBC – best with in first m of life

Urea cycle disorders



Neonatal Haemochromatosis

- NH is a syndrome in which severe liver disease associated with deposition of stainable iron in extrahepatic sites
- Supporting diagnostic features:
 - Presentation at birth
 - 80% Day 1
 - 93% Week 1
 - Jaundice (conjugated BR)
 - Moderately elevated alanine aminotransferase
 - ascites, edema, low albumin
 - coagulopathy
 - hypoglycaemia
 - Parenchymal iron deposition



Neonatal Haemochromatosis

- Alloimmune process
- 32 kd foetal liver antigen in the maternal blood
- demonstration of extra hepatic iron deposits sparing the reticuloendothelial system
- IVIG given at a dose of 1 gm/kg bodyweight weekly from the 18th week until the end of gestation
- Gestational Alloimmune liver disease (GALD)



Ferritin levels in neonatal liver failure due to neonatal haemachromatosis and other causes (Median and range)



Siderosis in buccal minor salivary glands



MRI



Treatment



IV immunoglobulin
exchange transfusion

Infiltrative

- Hemophagocytic Lymphohistiocytosis
- Inappropriate activation of T lymphocytes and macrophages



Wilson disease

- Autosomal recessive disorder,
- Coombs-negative hemolytic anaemia,
- Low ceruloplasmin
- low alkaline phosphatase.
- Antibodies might be positive
- Biopsy might not be possible



Is it worth squeezing the juice?

Value of liver biopsy



ALF Management

- General measures
- Actiology related treatment
- Management of specific complications
- Indications for Transplantation



General Measures

- Nurse in quite environment
- Avoid sedation
- Nutrition (1 gm/kg of protein) NG feeds / PN



Management

- Ventilation- Protect airway
- Fluids Hypoglycemia/ 4 to 6 mg/kg/min of G
- Infection

Bacterial -82%/ Fungal -34% in Grade $\frac{3}{4}$ encephalopathy not on prophylaxis. Add acyclovir in infants



Coagulopathy

- Vitamin K: Daily dose
- Platelets if <10,000/mm3
- For procedure 50 70,000 is adequete
- Cryo if fibrinogen < 100
- Recombinant activated factor VII/ FFP: give only for invasive procedures or active bleeding



Which Pressor?

- Norepinephrine
 - increase BP, CPP
 - little effect on ICP
- Vasopressin analouge
 - increase CPP
- Adrenaline Concerns Regarding Splanchnic Perfusion
- Hydrocortisone



Encephalopathy

Ammonia lowering agents Protein elemination Lactulose Gut decontamination Not helpful in acute /hyperacute setting

No role of prophylactic HS/ Mannitol/ steroids



Raised ICP

- Arterial ammonia correlates with raised ICP
- Risk of cerebral oedema high in younger age group
- Signs of raised ICP mannitol / HS
- No role of prophylactic HV/HS/ Mannitol/steroids

Neurologic Support; Arterial Ammonia and Risk of Cerebral Oedema



BERNAL W, ET AL. HEPATOLOGY 2007; 46:1844-52

Aetiology related treatment

- NH
- Autoimmune
- Tyrosinemia
- Galactosemia
- Herpes infection
- Paracetamol

IV IG Steroids NTBC Galactose free diet Aciclovir NAC



NAC in non-paracentamol ALF

- NAC did not improve 1-year survival in non-APAP PALF.
- 1-year LTx-free survival was significantly lower with NAC, particularly among those < 2 years old
- These results do not support broad use of NAC in non-APAP PALF



High volume plasma exchange in ALF

N = 182

survival was 58.7% (HVP) vs. 47.8% (Control)(p = 0.0083).

severe adverse events was similar in the two groups.

SIRS and sequential organ failure assessment (SOFA) scores fell in the treated group compared to control group, over the study period (p <0.001).

High-volume plasma exchange in patients with acute liver failure: An open randomised controlled trial<u>Fin Stolze LarsenCorrespondence information about the author Fin Stolze LarsenEmail the author Fin Stolze Larsen, Lars Ebbe Schmidt, Christine Bernsmeier, Allan Rasmussen, Helena Isoniemi, Vishal C. Patel, Evangelos Triantafyllou, William Bernal, Georg Auzinger, Debbie Shawcross, Martin Eefsen, Peter Nissen Bjerring, Jens Otto Clemmesen, Krister Hockerstedt, Hans-Jørgen Frederiksen, Bent Adel Hansen, Charalambos G. Antoniades⁺, Julia Wendon⁺</u>



When to transplant

• INR > 4

or

• Factor V < 30%





New Wilson's Index

Score	Bilirubin	INR	AST	WCC	Albumin
	(µmol/l)		(IU/I)	(10 ⁹ /l)	(g/l)
0	0 - 100	0 - 1.29	0 - 100	0 - 6.7	>45
1	101 - 150	1.3 - 1.6	101 - 150	6.8 - 8.3	34 - 44
2	151 - 200	1.7 - 1.9	151 - 200	8.4 - 10.3	25 - 33
3	201 - 300	2.0 - 2.4	201 - 300	10.4 - 15.3	21 - 24
4	> 301	> 2.5	> 301	> 15.4	0 - 20

Orthotopic or Whole liver Tx

Donor



Patient with liver failure





Auxiliary Liver tx

Donor







Successful liver regeneration



FIG.1 Serial DISIDA scan at 1, 24 and 30 months after APOLT showing gradual recovery of native liver (right lobe) function (a,c,e); and corresponding CT images of gradual volumetric regeneration of native liver (right lobe) (b,d,f). L: left lobe (transplanted liver), R; right lobe (native liver).



Hepatocyte tx







Liver cell infusion







Take home message

- New definition for ALF
- Neonatal Hemochromatosis is not metabolic condition
- ALF and transplant criteria are not same
- Supportive measures essential
- Auxiliary transplant is new option
- Cell transplant and dialysis still experimental



Thank you

